Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Sutro Biopharma, Inc.

Sutro Biopharma, Inc. is a biotechnology company focused on clinical stage drug discovery, development, and manufacturing. The company specializes in precisely designed cancer therapeutics, as self-described.

msh id	COM:SUTROBIO
symbol	STRO
name	Sutro Biopharma, Inc.
homepage url	https://www.sutrobio.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	300
crunchbase url	-
linkedin url	-
founders	-

market cap	294.46M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.24
growth cost of revenue	-0.18
growth depreciation and amortization	0.97
growth ebitda	0.34
growth ebitda ratio	0.71
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.05
growth gross profit	1.47
growth gross profit ratio	0.09

COM:SUTROBIO

Sutro Biopharma, Inc.

Last Close

2.67

21/11 20:29

Market Cap

294.46M

Beta: -

Volume Today

762.56K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	243.01M
cost of revenue	243.01M
depreciation and amortization	6.82M
ebitda	-82.46M
ebitda ratio	-0.54
eps	-1.78
eps diluted	-1.78
operating expenses	236.19M
operating income	-89.28M
operating income ratio	-0.58

accounts receivables	-28.96M
capital expenditure	-4.32M
cash at beginning of period	48.13M
cash at end of period	70.14M
inventory	-
working capital ttm	307.65M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-